Revision as of 14:25, 17 December 2024 editMo18ekula (talk | contribs)260 edits ←Created page with '{{Infobox drug | drug_name = RX 871024 | image = RX 871024.svg | width = 250px | caption = <!-- Clinical data --> | pronounce = | tradename = | Drugs.com = | MedlinePlus = | licence_CA = | licence_EU = | DailyMedID = | licence_US = | pregnancy_AU = | pregnancy_category = | dependency_liability = | addiction_liability = | routes_of_administration = | class = | ATC_prefix = | ATC_suffix = <!-- Legal status --> | legal_status = <!-- Pharma...' | Revision as of 14:26, 17 December 2024 edit undoMo18ekula (talk | contribs)260 editsNo edit summaryNext edit → | ||
Line 61: | Line 61: | ||
To treat diabetes. The design is an attempt to generate an analog of Idazoxan.<ref>Denis Bigg, et al. US4659731 (1987 to Synthelabo SA).</ref><ref> Fagan, Gay P.; Chapleo, Christopher B.; Lane, Anthony C.; Myers, Malcolm; Roach, Alan G.; Smith, Colin F. C.; Stillings, Michael R.; Welbourn, Anthony P. (1988). "Indoline analogs of idazoxan: potent .alpha.2-antagonists and .alpha.1-agonists". Journal of Medicinal Chemistry. 31 (5): 944–948. doi:10.1021/jm00400a009.</ref> | To treat diabetes. The design is an attempt to generate an analog of Idazoxan.<ref>Denis Bigg, et al. US4659731 (1987 to Synthelabo SA).</ref><ref> Fagan, Gay P.; Chapleo, Christopher B.; Lane, Anthony C.; Myers, Malcolm; Roach, Alan G.; Smith, Colin F. C.; Stillings, Michael R.; Welbourn, Anthony P. (1988). "Indoline analogs of idazoxan: potent .alpha.2-antagonists and .alpha.1-agonists". Journal of Medicinal Chemistry. 31 (5): 944–948. doi:10.1021/jm00400a009.</ref> | ||
The structure is a Imidazoline and also an N-phenylindole. | |||
==Synthesis== | ==Synthesis== | ||
Prec:<ref> Dolby, Lloyd J.; Lord, Pierre D. (1969). "2-Alkylidene-2H-indole intermediates. Thermolysis of 2-hydroxydiphenylmethylindole". The Journal of Organic Chemistry. 34 (10): 2988–2993. doi:10.1021/jo01262a042.</ref> Patent:<ref>Christopher B. Chapleo & Gay P. Fagan, US5385919 (1995 to Reckitt & Colman Products Limited).</ref> | Prec:<ref> Dolby, Lloyd J.; Lord, Pierre D. (1969). "2-Alkylidene-2H-indole intermediates. Thermolysis of 2-hydroxydiphenylmethylindole". The Journal of Organic Chemistry. 34 (10): 2988–2993. doi:10.1021/jo01262a042.</ref> Patent:<ref>Christopher B. Chapleo & Gay P. Fagan, US5385919 (1995 to Reckitt & Colman Products Limited).</ref> | ||
Line 71: | Line 72: | ||
{{Oral hypoglycemics}} | {{Oral hypoglycemics}} | ||
] | ] | ||
] |
Revision as of 14:26, 17 December 2024
Identifiers | |
---|---|
IUPAC name
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
Chemical and physical data | |
Formula | C17H15N3 |
Molar mass | 261.328 g·mol |
3D model (JSmol) | |
SMILES
| |
InChI
|
To treat diabetes. The design is an attempt to generate an analog of Idazoxan.
The structure is a Imidazoline and also an N-phenylindole.
Synthesis
Prec: Patent:
Ex 1: The reaction between ethyl 1-phenyl-1H-indole-2-carboxylate (1) and ethylenediamine (2) gives RX 871024 (3). Also, reaction of 1-phenylindole-2-carbonitrile, PC20095505 with ethylenediamine monotosylate gives higher yield.
References
- Denis Bigg, et al. US4659731 (1987 to Synthelabo SA).
- Fagan, Gay P.; Chapleo, Christopher B.; Lane, Anthony C.; Myers, Malcolm; Roach, Alan G.; Smith, Colin F. C.; Stillings, Michael R.; Welbourn, Anthony P. (1988). "Indoline analogs of idazoxan: potent .alpha.2-antagonists and .alpha.1-agonists". Journal of Medicinal Chemistry. 31 (5): 944–948. doi:10.1021/jm00400a009.
- Dolby, Lloyd J.; Lord, Pierre D. (1969). "2-Alkylidene-2H-indole intermediates. Thermolysis of 2-hydroxydiphenylmethylindole". The Journal of Organic Chemistry. 34 (10): 2988–2993. doi:10.1021/jo01262a042.
- Christopher B. Chapleo & Gay P. Fagan, US5385919 (1995 to Reckitt & Colman Products Limited).